|Videos|December 15, 2022

EP 12A: Managing Thrombocytopenia in Patients receiving Chemotherapy for ES-SCLC

Author(s)Luis E. Raez, MD

Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.

Episodes in this series

EP. 1 EP. 1: Extensive-Stage Small Cell Lung Cancer Treatment Landscape

EP. 1 EP. 1: Extensive-Stage Small Cell Lung Cancer Treatment Landscape

EP. 2 EP. 2A: Treatment Challenges and Unmet Needs in Extensive-Stage Small Cell Lung Cancer

EP. 2 EP. 2A: Treatment Challenges and Unmet Needs in Extensive-Stage Small Cell Lung Cancer

EP. 3 EP. 2B: Challenges Affecting the Management of Extensive-Stage Small Cell Lung Cancer

EP. 3 EP. 2B: Challenges Affecting the Management of Extensive-Stage Small Cell Lung Cancer

EP. 4 EP. 3: Management of Extensive-Stage Small Cell Lung Cancer Treatment-Related Events

EP. 4 EP. 3: Management of Extensive-Stage Small Cell Lung Cancer Treatment-Related Events

EP. 5 EP. 4A: The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC

EP. 5 EP. 4A: The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC

EP. 6 EP. 4B: Considering Chemotherapy-Induced Myelosuppression and the Impact of Trilaciclib on Its Management

EP. 6 EP. 4B: Considering Chemotherapy-Induced Myelosuppression and the Impact of Trilaciclib on Its Management

EP. 7 EP. 5: Clinical Trial Evidence for the Myeloprotective Benefit of Trilaciclib for Chemotherapy-Induced Myelosuppression

EP. 7 EP. 5: Clinical Trial Evidence for the Myeloprotective Benefit of Trilaciclib for Chemotherapy-Induced Myelosuppression

EP. 8 EP. 6A: Benefits of Using Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer in Clinical Practice

EP. 8 EP. 6A: Benefits of Using Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer in Clinical Practice

EP. 9 EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer

EP. 9 EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer

EP. 10 EP. 7: Clinical Trial Evidence for Chemoprotectant Benefit of ALRN-6924 for Chemotherapy-Induced Myelosuppression

EP. 10 EP. 7: Clinical Trial Evidence for Chemoprotectant Benefit of ALRN-6924 for Chemotherapy-Induced Myelosuppression

EP. 11 EP. 8A: Considerations for Reactive and Proactive Approaches to the Management of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

EP. 11 EP. 8A: Considerations for Reactive and Proactive Approaches to the Management of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

EP. 12 EP. 8B: Reactive and Proactive Treatment Approaches for the Management of Chemotherapy-Induced Myelosuppression

EP. 12 EP. 8B: Reactive and Proactive Treatment Approaches for the Management of Chemotherapy-Induced Myelosuppression

EP. 13 EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data

EP. 13 EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data

Expert on SCLC

EP. 14 EP. 10A: Impact of Trilaciclib on Chemotherapy-Induced Myelosuppression in Patients with ES-SCLC

EP. 15 Episode 10B: Impact of Trilaciclib on Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC

EP. 15 Episode 10B: Impact of Trilaciclib on Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC

Expert on SCLC

EP. 16 Episode 11A: Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment

Lungs

EP. 17 Episode 11B: The Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment

Expert on SCLC

EP. 18 EP 12A: Managing Thrombocytopenia in Patients receiving Chemotherapy for ES-SCLC

Image of lungs

EP. 19 EP 12B: Management of Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC

ByAndrea Eleazar, MHS

September 2nd 2026

Abenacianine Identifies Occult Lung Tumors, Improves Surgical Margins

BySabrina Serani,Gavin M. Wright, MBBS, FRACS, PhD

September 2nd 2026

FDA Type C Meeting Supports Phase 3 Design for DLL3-Targeted ADC in ES-SCLC

ByAndrea Eleazar, MHS

September 1st 2026

Platinum/Pemetrexed Active in Mesothelioma After First-Line Immunotherapy

ByTargeted Oncology Staff

August 22nd 2026

FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC

ByTargeted Oncology Staff

August 19th 2026

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

North Carolina Oncology Association

North Carolina Oncology Association

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Module 4: Breast Surgery (2025)

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Module 5: Breast Radiation Therapy (2025)

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Module 3: Pathology And Biomarkers (2025)

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Module 2: Breast Imaging (2025)

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Module 9: Toxicity Management And Survivorship Considerations (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Type C Meeting Supports Phase 3 Design for DLL3-Targeted ADC in ES-SCLC

FDA Approval Sought for Selinexor Plus Ruxolitinib in Myelofibrosis

Zanidatamab/Chemo Achieves OS Benefit in HER2+ Gastroesopheageal Cancer

Gynecologic Cancer Trends, Testing, and Treatment Advances Explained

FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia